Dermata Therapeutics, Inc. has 12 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Proehl Gerald T | 17.3% | 694,687 | SCHEDULE 13D/A, 2026-02-23 | 2026-02-19 |
| Kyri K. Van Hoose | 9% | 384,352 | SCHEDULE 13D, 2026-06-01 | 2026-05-27 |
| Armistice Capital, LLC | 4.99% | 53,910 | SCHEDULE 13G/A, 2026-02-18 | 2025-12-31 |
| Mitchell P. Kopin | 4.99% | 211,246 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 |
| Bigger Capital Fund L P | 1.87% | 75,200 | SCHEDULE 13G/A, 2026-04-22 | 2026-03-31 |
Purpose of Transaction (Item 4)
Kyri K. Van Hoose
The Reporting Person acquired the securities reported herein for investment purposes. The Reporting Person reserves the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed of, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Person, market conditions or other factors. The Reporting Person serves as Chief Financial Officer of the Issuer, and in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person reserves the right to change her purpose and to formulate and implement plans or proposals with respect to the Issuer at any time and from time to time. Any such action may be made alone or in conjunction with other shareholders, potential acquirers, financing sources and/or other third parties and could include one or more purposes, plans or proposals that relate to or would result in actions required to be reported herein in accordance with Item 4 of Schedule 13D. Other than as described herein, the Reporting Person currently has no plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a) through (j) of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-06-01
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 9.99% | SCHEDULE 13G |
| 2025-12-30 | Bigger Michael | 7.43% | SCHEDULE 13G |
| 2026-01-02 | Mitchell P. Kopin | 5.5% | SCHEDULE 13G |
| 2026-01-08 | Proehl Gerald T | 24.7% | SCHEDULE 13D/A |
| 2026-02-02 | Proehl Gerald T | 19.6% | SCHEDULE 13D/A |
| 2026-02-09 | Bigger Michael | 9.89% | SCHEDULE 13G/A |
| 2026-02-17 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-02-18 | Armistice Capital, LLC | 4.99% | SCHEDULE 13G/A |
| 2026-02-23 | Proehl Gerald T | 17.3% | SCHEDULE 13D/A |
| 2026-04-22 | Bigger Capital Fund L P | 1.87% | SCHEDULE 13G/A |
| 2026-05-13 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G/A |
| 2026-06-01 | Kyri K. Van Hoose | 9% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for Dermata Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.